South Korean medical robotics startup MedInTech has raised $25.7 million in Series C financing to expand its AI-powered robotic endoscopy portfolio and accelerate development of therapeutic and surgical technologies. The round was jointly led by existing investor Atinum Investment and new investor KB Investment, bringing the company’s cumulative funding to approximately $47.3 million. The capital will support research and development, regulatory approvals, manufacturing capacity and international commercialization.
MedInTech’s flagship product, INTION S, uses motor-driven controls and AI-based image recognition to support endoscope navigation and autonomous steering. A clinical trial involving 178 adults at Seoul National University Hospital compared the system with conventional mechanically controlled endoscopes. The study, published in Scientific Reports, reported non-inferiority in key maneuverability measurements, along with reductions in clinician physical fatigue and workload. The company has also commercialized INTION DEEPEYE, AI software designed to detect and classify abnormal regions in gastric and colon endoscopy images.
The company plans to move beyond diagnostic endoscopy into therapeutic applications and surgical robotics, including next-generation treatment instruments and platforms. INTION S has recorded initial sales in South Korea, Thailand, the Philippines and Mongolia, although detailed installation and revenue figures have not been disclosed. Further adoption will depend on regulatory approvals, clinical validation, clinician acceptance and manufacturing scale-up. The available clinical findings support technical feasibility but do not yet establish improved patient outcomes or cost-effectiveness.
